title: Alterations of bone mineral metabolism of children with different cell lineage types of acute lymphoblastic leukaemia under chemotherapy.
abstract: BACKGROUND
  Children with haematological malignancies such as acute lymphoblastic leukaemia (ALL) may have alteration of bone mineral metabolism therefore increased risk for osteopenia and osteoporosis.
  
  
  METHODS
  The purpose of this study was to examine the alterations of bone mineral metabolism in two groups of children (n=42) according to immunophenotyping (B-cell type, T-cell type) both quantitative (bone mineral density z-scores) and qualitative (serum osteocalcin - OC and carboxyl-terminal telopeptide of human type I collagen - ICTP) during diagnosis (T=0), after the intensified chemotherapy period (T=0.5) and the consolidation period (T=1).
  
  
  RESULTS
  According to our results 15 patients had osteopenia and 1 child developed osteoporosis at T=0.5 and 13 patients had osteopenia at T=1. Mean BMD z-score was significantly decreased in both groups during chemotherapy and especially statistically significant decline of T-cell type ALL group compared with B-cell type ALL patients. OC mean level remains in low levels for both groups reaching in plateau during chemotherapy and ICTP level was increased in T-cell type ALL group of patients compared with B-cell type in both periods of chemotherapy.
  
  
  CONCLUSIONS
  It seems that not only the combination of chemotherapeutic agents but also the cell lineage of ALL are important parameters of altering bone mineral metabolism.
authors: A
authors: A
authors: Tragiannidis
authors: Ch
authors: Ch
authors: Dokos
authors: V
authors: V
authors: Sidi
authors: Th
authors: T
authors: Papageorgiou
authors: D
authors: D
authors: Koliouskas
authors: M
authors: M
authors: Karamouzis
authors: Ch
authors: Ch
authors: Papastergiou
authors: I
authors: I
authors: Tsitouridis
authors: G
authors: G
authors: Katzos
authors: I
authors: I
authors: Rousso
authors: F
authors: F
authors: Athanassiadou-Piperopoulou
references: Pediatr Res. 2000 Oct;48(4):490-6
references: 11004240
references: Clin Endocrinol (Oxf). 2005 Jul;63(1):1-9
references: 15963054
references: J Pediatr Oncol Nurs. 1998 Apr;15(2):72-84; quiz 85-9
references: 9597816
references: Eur J Cancer. 1999 Nov;35(12):1693-7
references: 10674015
references: N Engl J Med. 1974 Apr 18;290(16):867-71
references: 4816960
references: J Bone Miner Metab. 2003;21(3):172-8
references: 12720052
references: Calcif Tissue Int. 2002 May;70(5):408-15
references: 12055656
references: Pediatr Blood Cancer. 2006 Jan;46(1):88-93
references: 15926166
references: Bone. 2007 Oct;41(4):486-95
references: 17706477
references: J Bone Miner Res. 1995 Jun;10(6):874-80
references: 7572311
references: J Clin Oncol. 1998 Jun;16(6):2070-9
references: 9626206
references: Eur J Cancer. 1999 Jun;35(6):960-7
references: 10533479
references: Clin Chem. 1997 Mar;43(3):543-5
references: 9068603
references: Pediatr Hematol Oncol. 2005 Jun;22(4):285-9
references: 16020115
references: Cancer. 2007 Apr 1;109(7):1420-31
references: 17326055
references: Oncologist. 2001;6(3):278-85
references: 11423675
references: J Pediatr. 2002 Aug;141(2):204-10
references: 12183715
references: Pediatr Blood Cancer. 2008 Feb;50(2 Suppl):469-73; discussion 486
references: 18064652
references: Cancer. 1987 Jan 15;59(2):346-50
references: 3467823
references: Pediatr Blood Cancer. 2008 Feb;50(2 Suppl):474-8; discussion 486
references: 18064660